导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 19.19% | 435/4773 |
| 近一周 | 0.11% | 808/5465 |
| 近一月 | -5.55% | 3800/5421 |
| 近一季 | -13.27% | 4127/5231 |
| 近半年 | 18.24% | 272/4920 |
| 近一年 | 24.32% | 343/4394 |
| 近两年 | 138.91% | 318/2954 |
| 近三年 | 87.78% | 208/2253 |
| 成立以来 | 108.12% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.71% 3362/4961 |
59.13% 420/5312 |
- - |
- - |
| 2025 | 55.43% 324/4813 |
2.51% 1353/3635 |
3.15% 1139/4076 |
48.13% 393/4524 |
-0.77% 2635/4813 |
| 2024 | 10.15% 1432/3463 |
-3.24% 1480/2808 |
-5.06% 1632/3014 |
21.25% 603/3129 |
-1.11% 1590/3463 |
| 2023 | -23.20% 1954/2656 |
0.69% 1713/2280 |
-7.69% 1889/2385 |
-10.01% 1931/2515 |
-8.19% 2260/2655 |
| 2022 | -30.46% 1632/2207 |
-17.82% 1267/1919 |
8.78% 327/2016 |
-21.22% 1898/2113 |
-1.26% 1687/2208 |
| 2021 | 6.41% 515/1822 |
-5.44% 923/1255 |
20.34% 149/1330 |
-6.49% 940/1466 |
- 1182/1822 |
| 2020 | 74.61% 58/1250 |
4.75% 62/1028 |
28.76% 94/1067 |
10.11% 587/1164 |
17.57% 120/1184 |
| 2019 | - - |
- - |
- - |
8.07% 71/850 |
10.55% 122/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华夏战略新兴成指ETF联接C VS. 长安沪深300非周期A(740101) |